- In March 2024, Baxter International launched a new hemostatic product with enhanced efficacy and ease of use. This product is designed to provide rapid and sustained hemostasis in a variety of surgical settings.
- In February 2024, Johnson & Johnson received FDA approval for a new sealant indicated for use in minimally invasive surgical procedures. This sealant offers improved tissue adhesion and reduces the risk of leakage.
- In January 2024, Medtronic announced a partnership with a leading research institution to develop novel biosurgery solutions using advanced biomaterials. This collaboration aims to address unmet needs in surgical hemostasis and tissue repair.
- In December 2023, Sanofi expanded its biosurgery portfolio with the acquisition of a company specializing in adhesion prevention products. This acquisition strengthens Sanofi's position in the biosurgery market and provides access to innovative technologies.
- In November 2023, Integra LifeSciences launched a next-generation bone graft substitute designed to promote faster and more complete bone healing. This product incorporates novel biomaterials and cellular components to enhance its osteogenic properties.
